New data could put Roche’s Tecentriq first in squamous lung cancer
Roche’s Tecentriq has met its targets in a clinical trial involving previously-untreated people with a form of advanced squamous lung cancer, stealing a march on its immuno-oncology rivals.
The phase III IMpower131 study showed that adding the PD-L1 inhibitor to standard first-line chemotherapy with carboplatin and Celgene’s Abraxane (nab-paclitaxel) in patients with advanced squamous non-small cell lung cancer (NSCLC) reduced the risk of disease worsening or death compared to chemotherapy alone.
There has been no impact on overall survival so far, the trial’s other primary endpoint, and Roche says it is continuing the study as planned. According to clinicaltrials.gov the primary completion date for the study is in August with follow-up until February 2023.
Read more: http://www.pmlive.com/pharma_news/new_data_could_put_roches_tecentriq_first_in_squamous_lung_cancer_1228404
The phase III IMpower131 study showed that adding the PD-L1 inhibitor to standard first-line chemotherapy with carboplatin and Celgene’s Abraxane (nab-paclitaxel) in patients with advanced squamous non-small cell lung cancer (NSCLC) reduced the risk of disease worsening or death compared to chemotherapy alone.
There has been no impact on overall survival so far, the trial’s other primary endpoint, and Roche says it is continuing the study as planned. According to clinicaltrials.gov the primary completion date for the study is in August with follow-up until February 2023.
Read more: http://www.pmlive.com/pharma_news/new_data_could_put_roches_tecentriq_first_in_squamous_lung_cancer_1228404
